SYNTHESIS & CHARACTERIZATION OF NEW MACROMOLECULAR CONTRAST AGENTS

合成

• 批准号: 7601814
• 负责人: Robert Charles Brasch
• 金额: $ 0.03万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-30 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7601814
• 关键词: Blood; Categories; Characteristics; Chemical Structure; Class; Computer Retrieval of Information on Scientific Projects Database; Contrast Media; Data; Diagnostic; Funding; Grant; Image; Institution; Mass Spectrum Analysis; Measurement; Medical Imaging; Methods; Microvascular Permeability; Molecular; Molecular Weight; Organ; Pharmacologic Substance; Procedures; Property; Research; Research Personnel; Resources; Role; Source; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Structure; Tissues; United States National Institutes of Health; chemical synthesis; size; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Introduction: Imaging contrast agents (or contrast media) are a category of diagnostic pharmaceuticals for enhancing the image contrast of organs/tissues and for displaying the organ function in medical imaging. Macromolecular contrast agents have found their important role in the characterization of microvascular permeability of tumor vessels, due to their blood-pool characteristics. New dendritic contrast agents with well-defined structure, high degree of size homogeneity, varying molecular weights and polyethyleneglycol (PEG) cores, will be synthesized. Their average molecular weights (MW) and MW distribution will be obtained from mass spectrometry, which info will be highly helpful for the chemical synthesis and for the study of their structure-property relationship. In addition, some new small molecular intermediates, which are attributed to the image contrast, need the structure characterization by mass spectrometry, too. Methods: For different macromolecular derivatives (MW 3,000 - 150,000), MALDI-MS could be used for the measurements of their MW and distributions in MW. For small molecular compounds (MW 500 - 2000), ESI-MS or other approaches may be applicable. Results & Discussion: Mass spectra data will be correlated with the data from physical and imaging measurements, the relationship between chemical structure and physical (or imaging) properties will be sought for this new class of macromolecular contrast agents. During the synthesis, the mass spectra data will be highly helpful in the guidance and optimization of synthetic procedures.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 简介：成像造影剂（或造影剂）是一类用于增强器官/组织的图像对比度并在医学成像中显示器官功能的诊断药物。由于其血池特性，大分子造影剂在表征肿瘤血管的微血管通透性方面发挥着重要作用。将合成具有明确结构、高度尺寸均匀性、不同分子量和聚乙二醇（PEG）核心的新型树枝状造影剂。通过质谱法可以获得它们的平均分子量（MW）和MW分布，这些信息对于化学合成和结构-性能关系的研究非常有帮助。此外，一些新的小分子中间体由于图像对比度的原因，也需要通过质谱进行结构表征。 方法：对于不同的大分子衍生物（MW 3,000 - 150,000），MALDI-MS可用于测量其MW及其分布。对于小分子化合物（MW 500 - 2000），ESI-MS 或其他方法可能适用。 结果与讨论：质谱数据将与物理和成像测量的数据相关联，将寻找此类新型大分子造影剂的化学结构和物理（或成像）特性之间的关系。在合成过程中，质谱数据对于指导和优化合成程序将非常有帮助。